China News Service, February 25. According to the website of the State Food and Drug Administration, on the 25th, the State Food and Drug Administration approved the new coronavirus inactivated vaccine (Vero cell) of Sinopharm Zhongsheng Wuhan Co., Ltd., and the reorganization of the new coronavirus by Cansino Biotech Co., Ltd. Application for registration of viral vaccine (type 5 adenovirus vector).
On February 25, the National Medical Products Administration approved the registration application of the new coronavirus inactivated vaccine (Vero cell) of the Sinopharm Wuhan Institute of Biological Products Co., Ltd. with conditions.
The vaccine is suitable for preventing the disease (COVID-19) caused by the new coronavirus infection.
In addition, the State Drug Administration has conditionally approved the registration application for the recombinant new coronavirus vaccine (type 5 adenovirus vector) of Cansino Biotech.
This vaccine is the first domestically-made adenovirus vector new coronavirus vaccine approved and is suitable for the prevention of diseases caused by new coronavirus infection (COVID-19).
The State Food and Drug Administration stated that in accordance with the relevant provisions of the Vaccine Management Law and the Drug Management Law, emergency review and approval will be conducted in accordance with the special drug approval procedures, and the application for listing registration will be approved with conditions.
The State Food and Drug Administration requires the holder of the vaccine marketing license to continue to carry out relevant research work, complete the conditional requirements, and submit follow-up research results in time.